Numerical optimization of gene electrotransfer into muscle tissue
© Anze et al; licensee BioMed Central Ltd. 2010
Received: 3 September 2010
Accepted: 4 November 2010
Published: 4 November 2010
Electroporation-based gene therapy and DNA vaccination are promising medical applications that depend on transfer of pDNA into target tissues with use of electric pulses. Gene electrotransfer efficiency depends on electrode configuration and electric pulse parameters, which determine the electric field distribution. Numerical modeling represents a fast and convenient method for optimization of gene electrotransfer parameters. We used numerical modeling, parameterization and numerical optimization to determine the optimum parameters for gene electrotransfer in muscle tissue.
We built a 3D geometry of muscle tissue with two or six needle electrodes (two rows of three needle electrodes) inserted. We performed a parametric study and optimization based on a genetic algorithm to analyze the effects of distances between the electrodes, depth of insertion, orientation of electrodes with respect to muscle fibers and applied voltage on the electric field distribution. The quality of solutions were evaluated in terms of volumes of reversibly (desired) and irreversibly (undesired) electroporated muscle tissue and total electric current through the tissue.
Large volumes of reversibly electroporated muscle with relatively little damage can be achieved by using large distances between electrodes and large electrode insertion depths. Orienting the electrodes perpendicular to muscle fibers is significantly better than the parallel orientation for six needle electrodes, while for two electrodes the effect of orientation is not so pronounced. For each set of geometrical parameters, the window of optimal voltages is quite narrow, with lower voltages resulting in low volumes of reversibly electroporated tissue and higher voltages in high volumes of irreversibly electroporated tissue. Furthermore, we determined which applied voltages are needed to achieve the optimal field distribution for different distances between electrodes.
The presented numerical study of gene electrotransfer is the first that demonstrates optimization of parameters for gene electrotransfer on tissue level. Our method of modeling and optimization is generic and can be applied to different electrode configurations, pulsing protocols and different tissues. Such numerical models, together with knowledge of tissue properties can provide useful guidelines for researchers and physicians in selecting optimal parameters for in vivo gene electrotransfer, thus reducing the number of animals used in studies of gene therapy and DNA vaccination.
In the last decades advances in genetic research offered a set of new therapies for various diseases based on in vivo genetic manipulations. The most developed of them are gene therapy and DNA vaccination, which have already been tested in several clinical trials [1–4]. While gene therapy works by delivering therapeutic genes into target cells to express themselves and produce proteins acting directly against a given disease, in genetic vaccination the produced proteins act as antigens that illicit an immune response [5, 6]. In the future, genetic therapies could represent an effective treatment for degenerative diseases, cancer, infections and cardiovascular diseases, for which currently no adequate treatments are available [3, 7–10].
The first step for gene therapy and DNA vaccination is efficient transfer of DNA molecules into target cells. In vitro, chemical, physical and biological methods have been successfully used for gene transfer [7, 11, 12]. However, there have been difficulties of translating these methods into in vivo settings. Currently, viral vectors boast the highest transfection efficiency, but this efficiency comes with an increased risk of viral infection [13, 14]. Therefore, alternative methods are being developed. One of the most promising physical methods for gene transfer in vivo is gene electrotransfer which, in comparison to viral vectors, is not hampered in terms of immunogenicity or pathogenicity. Gene electrotransfer combines the use of pDNA and local application of electric pulses, which increase the permeability of target cells (electroporation) for different molecules, including pDNA, and thus enable transfer of DNA into the cell. Compared to other physical and chemical methods, it was shown that gene electrotransfer is the most versatile and also the most efficient method in vivo compared to other methods. For example, the gene gun method is limited to exposed tissues while complexes of DNA and cationic lipids or polymers can be unstable, inflammatory and toxic . Gene electrotransfer has therefore great potential to be used in clinics for treatment of cancer and various chronic diseases [15–22], and also for DNA vaccination for prevention of various infectious diseases and HIV . Moreover, recently it was demonstrated that gene electrotransfer can be successfully applied as a method for DNA vaccination for cancer treatment [6, 23, 24], where DNA for a certain tumor antigen is transferred during remission and can thus prepare the immune system for a better response against the tumor cells during relapse of the disease.
Gene electrotransfer was demonstrated almost 30 years ago  when it was first shown that exposing cells to high-voltage electric pulses results in transfer of DNA molecules and expression of the delivered genes. Up to now, several steps that are involved in gene electrotransfer have been identified: electropermeabilization of the cell membrane, contact of pDNA with the cell membrane (formation of a DNA-membrane complex), translocation of pDNA across the membrane, transfer of pDNA to and into the nucleus and gene expression [26–29]. The effectiveness of electroporation and consequently of gene electrotransfer depends on pulse parameters, such as amplitude, duration, number, pulse repetition frequency and geometric properties of electrode and tissue/sample configuration [30–33]. These parameters define the duration of exposure to external electric field and the electric field strength, which have been shown to be the most important parameters in cell electroporation. Namely, molecular transport into and out of cells is observed only above a threshold value for reversible electroporation E > E rev . When electric field is further increased above the irreversible electroporation threshold E > E irr (or when longer and/or several pulses are used) the changes in the cell membrane become irreversible and cells die. Therefore for efficient gene electrotransfer it is crucial to choose an appropriate applied voltage/electrode configuration, such that the local electric field in the target tissue is between the reversible and irreversible electroporation threshold E rev > E > E irr , which enables gene transfer and preserves cell viability, thus enabling successful gene expression.
Gene electrotransfer was first demonstrated in vivo in 1998 by several independent studies [34–37]. It is currently being extensively studied on animal models in vivo for gene therapy [7, 16, 19, 30, 38, 39] as well as DNA vaccination [6, 23, 40]. In the last years the first human clinical trials have also started and also show encouraging results [18, 19, 41–43]. One of the major obstacles towards translating gene electrotransfer into clinical applications is its relatively low efficiency. Even though it was demonstrated that in skin [39, 44–50] and muscle tissue [34, 37, 51–56] prolonged expression of transfected genes can be achieved, the relative transfection rates have remained relatively low. In order to improve transfection efficiency the parameters of electric pulses have to be optimized depending on the type of electrodes used and specifically adjusted for each target tissue (e.g. muscle, skin, tumor tissue).
Several researchers have demonstrated that numerical modeling can be used to predict the extent of electroporation in biological tissues [57–64]. Also, numerical modeling and optimization have already been used for optimization of electric pulse parameters for electrochemotherapy of subcutaneous tumors, for tumor ablation with irreversible electroporation [63, 65–67] and recently, the first deep-seated tumor was treated with electrochemotherapy based on a numerical treatment plan . However, up to now there exists no such study which would use numerical modeling for optimization of gene electrotransfer.
In our present study we used 3D numerical modeling and numerical optimization to determine the best electrical parameters for efficient gene electrotransfer into muscle tissue, which is regarded by many as the "tissue of choice" for gene electrotransfer-based gene therapy and DNA vaccination [19, 30, 41, 69, 70]. We performed a parametric study to better understand how various electroporation parameters (applied voltage, number of electrodes used, electrode positions, insertion depth) affect the electric field distribution in muscle tissue, and numerical optimization of the parameters to demonstrate that such numerical "treatment planning" could be used by researchers and clinicians to better control the extent of electroporation in the target tissues. We compared different needle electrode configurations recommended in the literature for gene electrotransfer in large animals and humans and analyzed the effect of orientation of the electrodes (and thus the electric field) with respect to the orientation of muscle fibers. The methods used in this study and the obtained results can be used as guidelines for future numerical studies and planning of gene electrotransfer in vivo.
Model geometry and tissue properties
where σ is the tensor of electrical conductivity and u the electric potential. The boundary conditions used in our calculations were: 1) constant potential on the surface of the active parts of the electrodes and 2) insulation (n·J= 0) on the outer boundaries of the model.
where σ 1 and σ 2 are tensors of electrical conductivities of non-electroporated and electroporated tissues, respectively (see previous section), and E irr and E rev are the thresholds of irreversible and reversible electroporation, respectively. We approximated the dynamics of the conductivity changes during electroporation by performing several sequential calculation of the electric field distribution, while changing the conductivities according to Eq. 3. The details of the sequential analysis can be found in our previous work [57, 73].
The results of the numerical modeling were analyzed by calculating the volumes for reversibly and irreversibly electroporated muscle tissue, V rev and V irr , respectively, and total current through the tissue I. V rev was calculated by integrating the volume of muscle tissue, where conductivity has changed (σ xx , σ yy or σ zz ), while V irr by integrating the volume, where the electric field was over the irreversible electroporation threshold E > E irr .
The limit value for V irr (1 cm3) was based on our estimate of tissue damage produced by electrode insertion and the fact that some tissue damage is always present around needle electrodes during electroporation. The limit value for I (30 A) was based on the limitation of electroporation devices available on the market at the time of the study. By taking into account constraints for V irr and for I, extensive damage to muscle tissue is avoided and compliance with electric pulse generator limitations guaranteed.
where z i and m i are child chromosomes, x i and y i are parent chromosomes and a i and b i are numbers randomly chosen from the given intervals. The optimization was stopped after the chromosome with the highest objective function value has not improved in 20 iterations for more than 0.1%, which was interpreted as reaching a solution very close to the global optimum.
Two needle electrodes
Optimum gene electrotransfer parameters (z, ϕ, U) for two electrodes.
V rev [cm3]
V irr [cm3]
Increasing the depth of insertion (z) also produces higher objective function values, with Figure 4b suggesting a linear relationship between the two. Positioning the electrodes so that the electric field is perpendicular to the direction of muscle fibers produces objective functions up to 20% higher than the parallel orientation (Figure 4c), however slightly higher voltages had to be used to achieve this.
Figure 5 shows how increasing the voltage between electrodes affects the objective function. At lower voltages increasing the voltage increases the objective function, however after a peak is reached (1400 V) the objective function values start to sharply decrease, because the damage to tissue exceeds the values (V rev or I) tolerated by the objective function.
Six needle electrodes
Optimum gene electrotransfer parameters (b, z, ϕ, U) for six electrodes.
V rev [cm3]
V irr [cm3]
Figure 7 shows how increasing the voltage between the electrode rows affects the objective function: at lower voltages increasing the voltage increases the objective function, however after the maximum is reached (1400 V) the objective function values sharply decrease.
The optimization results for six electrodes are presented in Figure 9. In this case, the perpendicular orientation produced almost two times better results than the parallel orientation. Similarly as for two electrodes, the sequence of images in Figure 9 shows, how taking into account the changes in conductivity during electroporation increases the calculated volumes of reversible electroporation. When analyzing how V rev increases with consecutive steps we obtained that it is a highly non-linear function where in the first step the biggest increase occurs; for two electrodes the increase is 2.5 times after the first step and 3.1 times at the final sequence; for six electrodes the increase in V rev after the first step is 2.9 times and 3.1 at the end of the sequence. The changes in V irr are negligible due to limitation of V irr < 1 cm3.
The difference between the perpendicular and parallel orientation can be illustrated by using the same parameters as determined for optimal solution shown in Figure 9, but by changing the direction of the generated electric field so that it is aligned with muscle fibers (ϕ = 0°). In this case, even more muscle volume becomes reversibly electroporated, however at the same time, the current flowing through the tissue (80.5 A) is much higher than the allowed current (30A) and also much higher compared to the current for the perpendicular orientation (29.1 A). Also approximately three times more tissue is irreversibly electroporated for parallel compared to perpendicular orientation (Figure 10).
Gene electrotransfer is already successfully being used for pDNA delivery in clinical applications, such as gene therapy and DNA vaccination. However, achieving an adequate extent of electroporation in target tissues can be difficult and requires extensive experimentation. Numerical modeling of electroporation can be used to complement in vivo experimentation as it allows planning of the electric field distribution beforehand. In this study we used 3D numerical modeling of muscle tissue, parameterization and numerical optimization to determine the affects of different geometrical and electrical parameters on the distribution of electric field in muscle tissue and the optimum parameters for gene electrotransfer in muscle tissue.
In the first part of this work we performed a parametric study to determine how various parameters affect the electric field distribution and volumes of tissue exposed to only reversible electric fields in muscle tissue, which is a prerequisite for effective gene electrotransfer. We determined that for large distances between the electrodes (d) and for placing the electrodes deeper into the muscle (z), the volumes of reversibly electroporated tissue (V rev ) increases. However, concurrently the volume of irreversibly electroporated tissue (V irr ) and total current through the tissue (I) also increase (see Tables 1 and 2, and Figures 4 and 6). Increases in V irr and I can be explained with higher voltage needed to reach the optimal electric field distribution at given d (Figures 4a and 6a), while for deeper insertion (larger z) V irr and I increase due to a larger surface area of the electrodes in the tissue. For two electrodes the limiting factor is V irr , which increases over the limit of 1 cm3 if voltage over 1600 V is used. For six electrodes I increases over 30 A before V irr gets over 1 cm3 and I can therefore be considered the limiting factor. Obviously, by choosing a different objective functions with different limit for V irr and I it is possible to control their importance and thereby adjust the results accordingly to the application and equipment used. The distance between the electrodes in a row (b) for six electrodes does not have much effect on V rev or V irr , except at very small distances b, which, as expected is not optimal since three electrodes with the same electric potential positioned very closely produce an electric field very similar to the one of only one electrode. The advantages of having several electrodes are therefore lost at small distances b.
When analyzing the effect of electrode orientation with respect to muscle fibers, we obtained that the perpendicular orientation of the electrodes (ϕ = 90°) is better than for the parallel orientation (ϕ = 0°) (Tables 1 and 2), since coverage of larger volumes of tissue with electric field above E rev and below E irr can be obtained. This can be mostly explained by the smaller volumes of irreversible electroporation achieved in the perpendicular orientation, while at the same time the current (I) flowing along the muscle fibers in the parallel orientations is much higher, therefore the current limitation of the objective function is achieved for lower voltages in the parallel orientation. The perpendicular orientation is significantly better for six needle electrodes (F ⊥ ≈ 2 × F ||) while for two needle electrodes the difference is not that large (20%). This is in agreement with the in vivo study in mice, where no statistical difference in gene expression was obtained between the perpendicular and parallel orientation for two needle electrodes . If possible, however, it is best to switch orientation of the electric field during the application of electric pulses for more effective gene electrotransfer, as already shown in several studies [46, 77, 78].
Furthermore, we analyzed the voltage dependence of the optimal solutions F(U) in parallel with the volume of irreversibly electroporated tissue V irr (U). We obtained that by increasing the applied voltage the volume of only reversibly electroporated tissue increased until an optimal voltage for a given electrode configuration was achieved (Figures 5 and 7). A further increase in the applied voltage lead to excessive tissue damage (large V irr ) and sharp decrease in the objective function value F. This strong dependency on pulse amplitude and relatively narrow window of pulse amplitudes for optimal treatment is in accordance with experimental observations [36, 58, 71, 79], where similarly transfection efficiency gradually increased above a threshold voltage, but further increase in voltage lead to a decrease in transfection.
When the results of the parametric study are examined in details, some surprising results can be seen. The relationship between the maximum objective function value and different parameters is not always a smooth curve (e.g. Figure 6b). This is due to an error introduced by relatively large discretization steps: as the objective functions were only evaluated for discrete values of the analyzed parameters some good solutions were missed. The discretization error is also responsible for a "strange" result for d = 56 mm, where in contrast to all other best solutions the parallel orientation produced better results than the perpendicular orientation. Also, for small distances d between the electrodes, I becomes the major limiting factor and therefore V irr does not come even close to the limiting value of 1 cm3 set in the objective function. The reason for this seems to be in the extreme non-linearity of the used model. Namely, for smaller electrode distances the electric currents get very high due to small resistance between the electrodes.
The parametric analysis enabled us to understand the relationship between different parameters that can affect the electric field distribution and thus gene electrotransfer. However, in order to optimize these parameters for a given clinical application (treatment planning) such an exhaustive search of the parameter space would take too long and demands very large computer resources. A better approach is, as already demonstrated for electrochemotherapy [67, 68] to directly apply an optimization algorithm to determine the optimal parameters. In our study, optimization took only 1.2 hours compared to 23 hours for the parametric study (for two electrodes) and 1.4 hours compared to 4 days for six electrodes. In our optimization study we used the same objective function as in the parametric study, only the parameter stepping was more accurate (see Methods). Therefore, as expected the obtained optimal solutions differ only slightly from the ones obtained in the parametric study (compare Figures 8 and 9 with Tables 1 and 2). This difference can be attributed to a smaller discretization step used in the optimization.
The electric field distributions of the optimal solutions are presented in Figure 8 (two electrodes) and Figure 9 (six electrodes). It can be seen that taking into account dynamic changes of conductivity during electroporation (sequential analysis) has a substantial effect on the final electric field distribution and V rev . Namely, in the first sequence only a small volume of muscle tissue is reversibly electroporated; while in the final sequence the whole volume between the electrodes reaches E > E rev (compare Figures 8a, b, c and 8d). This effect is more pronounced for six electrodes (Figures 9a, b, c and 9d). An array of six electrodes also provides a better electric field distribution overall, with higher objective function values (F 6 ≈ 3 × F 2 ). These results agree with our previous studies of optimization for electrochemotherapy [59, 66] that more electrodes enable coverage of larger volumes of tissue with a more homogeneous field. Six electrodes probably represent a good compromise between optimal electric field distributions and still keeping the invasiveness of the procedure relatively low. Nevertheless, using two electrodes can also produce good results, if parameters are select appropriately as already demonstrated [34, 80, 81].
The objective function used in our study was chosen according to the prerequisite for efficient gene electrotransfer: the cells should only be electroporated reversibly and not irreversibly. Our choice of objective function is also based on the experimental observation that the volume of electrotransfected muscle tissue correlates with the amount of expressed protein . In several studies of gene electrotransfer it was shown that larger transfected volumes are beneficial while for DNA vaccination the transfected volume is probably not such a critical parameter . The optimization and proper selection of objective function has to be done for a specific application together with researchers and physicians in clinics, based on complementary analysis and evaluation of pain and other undesired effects, such as tissue inflammation or thermal damage.
The presented analysis is partially similar to previous studies of optimization of parameters for electrochemotherapy [66–68] or irreversible ablation of tumors (IRE) [61, 63] where parameterization and/or optimization was also used to determine optimal electroporation parameters. However, there are two very important differences between our and the previous studies of ECT and IRE. Firstly, we included muscle anisotropy and sequential analysis in our models which was never done before and has also important effect on optimal solutions. Secondly, for ECT the objective function is set so that the most important parameter (weight) is the coverage of the whole tumor with E > E rev , while irreversible electroporation of the tumor is not severely penalized, since the goal of the therapy is tumor death; in EGT, however, it is enough that target tissue is just above the reversible electroporation threshold, while irreversible electroporation is not acceptable since it does not lead to expression of transfected genes. For this reason the additional constrain of V irr was put into the objective function, which penalizes solutions that would damage the tissue. For IRE a similarly reasoning would lead to another choice of objective function. Another important difference between the three applications is also what we want to treat: in ECT and IRE we want to treat a well defined target tissue and avoidance of electroporating vital organs is crucial, while for EGT of muscle tissue we want to reversibly electroporate large volumes.
In our numerical models joule heating was not analyzed as several studies have already shown that heating due to short 100 μs is negligible [82, 83] . Nevertheless, a conservative estimation of the temperature after the electric pulses (see Figure 9 for parameters used), where cooling of tissue due to heat conduction was not taken into account, was below 46 °C in the vicinity of the electrodes and below 38°C in the center between the electrodes, confirming that the proposed pulses would not cause extensive thermal damage. Furthermore, in our case the 30 A limit for total current prevented unwanted thermal damage. However, if longer trains of pulses were applied, e.g. 8 × 10 ms, thermal damage could become a the limiting factor that would have to be taken into account in the objective function.
We analyzed two and six needle electrode configurations, while plate electrodes were not analyzed since they cannot be applied for gene electrotransfer into muscle tissue in large animals and humans [84, 85]. Two needle electrodes were analyzed since they are widely used in in vivo gene electrotransfer, while six electrodes were chosen as they enable a more homogeneous electric field inside treated tissue and altogether more optimal solutions. The relatively large electrode distances used in the study were used to extent applicability of our results from small animals to large animals and humans.
One of the limitations of our numerical model is that it performs calculations on a limited domain of muscle tissue and that no other tissues (e.g. skin) are included. This is justified since we checked how the size of our model and boundaries affect the final results. No significant variation of the results (less than 2%) was obtained if the size of the model was increased for a factor of two. Also we have previously shown that if an additional layer with much lower conductivity is added on the top surface (resembling skin tissue) no significant effect is observed on the electric field distribution .
We further have to stress that the presented model and optimization was performed for relatively short electric pulses (8 × 100 μs) since the thresholds E rev and E irr are relatively well defined . In a variety of studies of in vivo gene electrotransfer it was shown that different electric pulse parameters can be used for efficient transfection : 1) relatively short pulses of 6 × 100 μs ; 2) relatively long and low pulses, e.g. 8 × 20 ms [35, 80, 87–89]; and 3) combination of high-voltage and low-voltage pulses [47, 71, 90–93]. To use the presented numerical optimization for different pulses, the electroporation thresholds would have to be determined and built into the electroporation models. The presented method of numerical modeling and optimization is generic and can be applied to different electrode configurations (e.g. plate, hexagonal, multi-array), electric pulse parameters (if thresholds E rev and E irr are known), other tissues (skin, liver, etc.) or performed for different definition of objective function defined on the basis of specific needs of given electroporation-based clinical applications such as gene therapy, DNA vaccination, electrochemotherapy or ablation by irreversible electroporation.
The presented numerical study of gene electrotransfer is the first study that enables optimization of electric parameters and electrode positions for gene electrotransfer in vivo. Moreover, it takes into account anisotropy of muscle tissue as well as dynamic changes of conductivity during electroporation by using sequential analysis. As such, it presents the first attempt to optimize electric pulse parameters and electrode positioning for gene electrotransfer. Our results can be used as guidelines for researchers and physicians in selecting optimal parameters for in vivo gene electrotransfer and thus indirectly also reduce the number of animals used in clinical studies of gene therapy and DNA vaccination.
The presented work was supported by several grants of the Slovenian Research Agency (ARRS).
- Cavazzana-Calvo M, Hacein-Bey S, Basile G, Dupuis-Girod S, Thrasher A, Wulffraat N, Sorensen R, Casanova J, Le Deist F, Fischer A: Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Blood 2000, 96: 2533.Google Scholar
- Hacein-Bey-Abina S, Von Kalle C, Schmidt M, McCormack MP, Wulffraat N, Leboulch P, Lim A, Osborne CS, Pawliuk R, Morillon E, Sorensen R, Forster A, Fraser P, Cohen JI, de Saint Basile G, Alexander I, Wintergerst U, Frebourg T, Aurias A, Stoppa-Lyonnet D, Romana S, Radford-Weiss I, Gross F, Valensi F, Delabesse E, Macintyre E, Sigaux F, Soulier J, Leiva LE, Wissler M, Prinz C, Rabbitts TH, Le Deist F, Fischer A, Cavazzana-Calvo M: LMO2-Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1. Science 2003, 302: 415–419. 10.1126/science.1088547View ArticleGoogle Scholar
- Mitsuyasu RT, Merigan TC, Carr A, Zack JA, Winters MA, Workman C, Bloch M, Lalezari J, Becker S, Thornton L, Akil B, Khanlou H, Finlayson R, McFarlane R, Smith DE, Garsia R, Ma D, Law M, Murray JM, von Kalle C, Ely JA, Patino SM, Knop AE, Wong P, Todd AV, Haughton M, Fuery C, Macpherson JL, Symonds GP, Evans LA, Pond SM, Cooper DA: Phase 2 gene therapy trial of an anti-HIV ribozyme in autologous CD34+ cells. Nat Med 2009, 15: 285–292. 10.1038/nm.1932View ArticleGoogle Scholar
- Luxembourg A, Evans C, Hannaman D: Electroporation-based DNA immunisation: translation to the clinic. Expet Opin Biol Ther 2007, 7: 1647–1664. 10.1517/14712522.214.171.1247View ArticleGoogle Scholar
- Stevenson FK, Ottensmeier CH, Rice J: DNA vaccines against cancer come of age. Curr Opin Immunol 2010, 22: 264–270. 10.1016/j.coi.2010.01.019View ArticleGoogle Scholar
- van Drunen Littel-van den Hurk S, Hannaman D: Electroporation for DNA immunization: clinical application. Expert Rev Vaccines 2010, 9: 503–517. 10.1586/erv.10.42View ArticleGoogle Scholar
- Prud'homme GJ, Glinka Y, Khan AS, Draghia-Akli R, others: Electroporation-enhanced nonviral gene transfer for the prevention or treatment of immunological, endocrine and neoplastic diseases. Curr Gene Ther 2006, 6: 243. 10.2174/156652306776359504View ArticleGoogle Scholar
- Sersa G, Cemazar M, Miklavcic D: Antitumor effectiveness of electrochemotherapy with cis-diamminedichloroplatinum(ii) in mice. Cancer Res 1995, 55: 3450–3455.Google Scholar
- Cavazzana-Calvo M, Thrasher A, Mavilio F: The future of gene therapy. Nature 2004, 427: 779–781. 10.1038/427779aView ArticleGoogle Scholar
- Cemazar M, Golzio M, Sersa G, Hojman P, Kranjc S, Mesojednik S, Rols MP, Teissie J: Control by pulse parameters of DNA electrotransfer into solid tumors in mice. Gene Ther 2009, 16: 635–644. 10.1038/gt.2009.10View ArticleGoogle Scholar
- Karmali PP, Chaudhuri A: Cationic liposomes as non-viral carriers of gene medicines: Resolved issues, open questions, and future promises. Med Res Rev 2007, 27: 696–722. 10.1002/med.20090View ArticleGoogle Scholar
- Parker AL, Newman C, Briggs S, Seymour L, Sheridan PJ: Nonviral Gene Delivery: Techniques and Implications for Molecular Medicine. Expert Rev Mol Med 2003, 5: 1–15. 10.1017/S1462399403006562View ArticleGoogle Scholar
- Ferber D: Gene therapy: Safer and virus-free? Science 2001, 294: 1638–1642. 10.1126/science.294.5547.1638View ArticleGoogle Scholar
- Lehrman S: Virus treatment questioned after gene therapy death. Nature 1999, 401: 517–518. 10.1038/43977View ArticleGoogle Scholar
- Mir LM: Therapeutic perspectives of in vivo cell electropermeabilization. Bioelectrochemistry 2001, 53: 1–10. 10.1016/S0302-4598(00)00112-4View ArticleGoogle Scholar
- Somiari S, Glasspool-Malone J, Drabick JJ, Gilbert RA, Heller R, Jaroszeski MJ, Malone RW: Theory and in vivo application of electroporative gene delivery. Mol Ther 2000, 2: 178–187. 10.1006/mthe.2000.0124View ArticleGoogle Scholar
- Gehl J: Electroporation for drug and gene delivery in the clinic: doctors go electric. Meth Mol Biol 2008, 423: 351. full_textView ArticleGoogle Scholar
- Daud A, DeConti R, Andrews S, Urbas P, Riker A, Sondak V, Munster P, Sullivan D, Ugen K, Messina J, Heller R: Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma. J Clin Oncol 2008, 26: 5896–5903. 10.1200/JCO.2007.13.9048View ArticleGoogle Scholar
- Hojman P: Basic Principles and Clinical Advancements of Muscle Electrotransfer. Curr Gene Ther 2010, 10: 128–138. 10.2174/156652310791110994View ArticleGoogle Scholar
- Andre F, Mir LM: DNA electrotransfer: its principles and an updated review of its therapeutic applications. Gene Ther 2004, 11: S33-S42. 10.1038/sj.gt.3302367View ArticleGoogle Scholar
- Favard C, Dean DS, Rols MP: Electrotransfer as a non viral method of gene delivery. Curr Gene Ther 2007, 7: 67–77. 10.2174/156652307779940207View ArticleGoogle Scholar
- Brown PA, Bodles-Brakhop AM, Pope MA, Draghia-Akli R: Gene therapy by electroporation for the treatment of chronic renal failure in companion animals. BMC Biotechnol 2009, 9: 4. 10.1186/1472-6750-9-4View ArticleGoogle Scholar
- Rice J, Ottensmeier CH, Stevenson FK: DNA vaccines: precision tools for activating effective immunity against cancer. Nat Rev Cancer 2008, 8: 108–120. 10.1038/nrc2326View ArticleGoogle Scholar
- Bodles-Brakhop AM, Draghia-Akli R: DNA vaccination and gene therapy: optimization and delivery for cancer therapy. Expet Rev Vaccine 2008, 7: 1085–1101. 10.1586/147605126.96.36.1995View ArticleGoogle Scholar
- Neumann E, Schaeferridder M, Wang Y, Hofschneider PH: Gene-transfer into mouse lyoma cells by electroporation in high electric-fields. Embo Journal 1982, 1: 841–845.Google Scholar
- Golzio M, Teissie J, Rols MP: Direct visualization at the single-cell level of electrically mediated gene delivery. Proc Natl Acad Sci USA 2002, 99: 1292–1297. 10.1073/pnas.022646499View ArticleGoogle Scholar
- Pavlin M, Flisar K, Kandušer M: The Role of Electrophoresis in Gene Electrotransfer. J Membrane Biol 2010, (236):75–79. 10.1007/s00232-010-9276-zGoogle Scholar
- Faurie C, Rebersek M, Golzio M, Kanduser M, Escoffre J, Pavlin M, Teissie J, Miklavcic D, Rols M: Electro-mediated gene transfer and expression are controlled by the life-time of DNA/membrane complex formation. J Gene Med 2010, 12: 117–125. 10.1002/jgm.1414View ArticleGoogle Scholar
- Kanduser M, Miklavcic D, Pavlin M: Mechanisms involved in gene electrotransfer using high- and low-voltage pulses - An in vitro study. Bioelectrochemistry 2009, 74: 265–271. 10.1016/j.bioelechem.2008.09.002View ArticleGoogle Scholar
- Cemazar M, Sersa G: Electrotransfer of therapeutic molecules into tissues. Curr Opin Mol Ther 2007, 9: 554–562.Google Scholar
- Escoffre J, Portet T, Wasungu L, Teissie J, Dean D, Rols M: What is (Still not) Known of the Mechanism by Which Electroporation Mediates Gene Transfer and Expression in Cells and Tissues. Mol Biotechnol 2009, 41: 286–295. 10.1007/s12033-008-9121-0View ArticleGoogle Scholar
- Gehl J: Electroporation: theory and methods, perspectives for drug delivery, gene therapy and research. Acta Physiol Scand 2003, 177: 437–447. 10.1046/j.1365-201X.2003.01093.xView ArticleGoogle Scholar
- Gilbert RA, Jaroszeski MJ, Heller R: Novel electrode designs for electrochemotherapy. Biochim Biophys Acta Gen Subj 1997, 1334: 9–14. 10.1016/S0304-4165(96)00119-5View ArticleGoogle Scholar
- Aihara H, Miyazaki J: Gene transfer into muscle by electroporation in vivo. Nat Biotechnol 1998, 16: 867–870. 10.1038/nbt0998-867View ArticleGoogle Scholar
- Rols MP, Delteil C, Golzio M, Dumond P, Cros S, Teissie J: In vivo electrically mediated protein and gene transfer in murine melanoma. Nat Biotechnol 1998, 16: 168–171. 10.1038/nbt0298-168View ArticleGoogle Scholar
- Suzuki T, Shin B, Fujikura K, Matsuzaki T, Takata K: Direct gene transfer into rat liver cells by in vivo electroporation. FEBS Lett 1998, 425: 436–440. 10.1016/S0014-5793(98)00284-1View ArticleGoogle Scholar
- Mir L, Bureau M, Rangara R, Schwartz B, Scherman D: Long-term, high level in vivo gene expression after electric pulse-mediated gene transfer into skeletal muscle. Compt Rendus Acad Sci III Sci Vie 1998, 321: 893–899.Google Scholar
- Heller R, Deconti R, Messina J, Andrews S, Urbas P, Ugen K, Puleo C, Sondak V, Riker A, Daud A: Gene therapy with plasmid IL-12 delivered by electroporation in patients with malignant melanoma: results of first human Phase I trial. EJC Supplements 2006, 4: 106–106.View ArticleGoogle Scholar
- Gothelf A, Eriksen J, Hojman P, Gehl J: Duration and level of transgene expression after gene electrotransfer to skin in mice. Gene Ther 2010, 17: 839–845. 10.1038/gt.2010.35View ArticleGoogle Scholar
- Liu F, Heston S, Shollenberger LM, Sun B, Mickle M, Lovell M, Huang L: Mechanism of in vivo DNA transport into cells by etectroporation: etectrophoresis across the plasma membrane may not be involved. J Gene Med 2006, 8: 353–361. 10.1002/jgm.851View ArticleGoogle Scholar
- Low L, Mander A, McCann K, Dearnaley D, Tjelle T, Mathiesen I, Stevenson F, Ottensmeier C: DNA Vaccination with Electroporation Induces Increased Antibody Responses in Patients with Prostate Cancer. Hum Gene Ther 2009, 20: 1269–1278. 10.1089/hum.2009.067View ArticleGoogle Scholar
- Sallberg M, Frelin L, Diepolder H, Jung M, Mathiesen I, Fons M, Hultcrantz R, Carlsson T, Weiland O: A first clinical trial of therapeutic vaccination using naked dna delivered by in vivo electroporation shows antiviral effects in patients with chronic hepatitis c. J Hepatol 2009, 50: 43. 10.1016/S0168-8278(09)60045-3View ArticleGoogle Scholar
- Heller L, Heller R: Electroporation Gene Therapy Preclinical and Clinical Trials for Melanoma. Curr Gene Ther 2010, 10: 312–317. 10.2174/156652310791823489View ArticleGoogle Scholar
- Mignet N, Vandermeulen G, Pembouong G, Largeau C, Thompson B, Spanedda M, Wasungu L, Rols M, Bessodes M, Bureau MF, Préat V, Scherman D: Cationic and anionic lipoplexes inhibit gene transfection by electroporation in vivo. J Gene Med 2010, 12: 491–500. 10.1002/jgm.1460View ArticleGoogle Scholar
- Bureau MF, Jugé L, Seguin J, Rager M, Scherman D, Mignet N: Muscle transfection and permeabilization induced by electrotransfer or pluronic ® L64Paired study by optical imaging and MRI. Biochim Biophys Acta Gen Subj 2010, 1800: 537–543. 10.1016/j.bbagen.2010.02.003View ArticleGoogle Scholar
- Heller R, Cruz Y, Heller LC, Gilbert RA, Jaroszeski MJ: Electrically Mediated Delivery of Plasmid DNA to the Skin, Using a Multielectrode Array. Hum Gene Ther 2010, 21: 357–362. 10.1089/hum.2009.065View ArticleGoogle Scholar
- Pavselj N, Preat V: DNA electrotransfer into the skin using a combination of one high- and one low-voltage pulse. J Contr Release 2005, 106: 407–415. 10.1016/j.jconrel.2005.05.003View ArticleGoogle Scholar
- Heller LC, Jaroszeski MJ, Coppola D, McCray AN, Hickey J, Heller R: Optimization of cutaneous electrically mediated plasmid DNA delivery using novel electrode. Gene Ther 2006, 14: 275–280. 10.1038/sj.gt.3302867View ArticleGoogle Scholar
- Vandermeulen G, Staes E, Vanderhaeghen ML, Bureau MF, Scherman D, Préat V: Optimisation of intradermal DNA electrotransfer for immunisation. J Contr Release 2007, 124: 81–87. 10.1016/j.jconrel.2007.08.010View ArticleGoogle Scholar
- Roos A, Eriksson F, Walters DC, Pisa P, King AD: Optimization of Skin Electroporation in Mice to Increase Tolerability of DNA Vaccine Delivery to Patients. Mol Ther 2009, 17: 1637–1642. 10.1038/mt.2009.120View ArticleGoogle Scholar
- Mathiesen I: Electropermeabilization of skeletal muscle enhances gene transfer in vivo. Gene Ther 1999, 6: 508–514. 10.1038/sj.gt.3300847View ArticleGoogle Scholar
- Satkauskas S, Andre F, Bureau MF, Scherman D, Miklavcic D, Mir LM: Electrophoretic component of electric pulses determines the efficacy of In Vivo DNA electrotransfer. Hum Gene Ther 2005, 16: 1194–1201. 10.1089/hum.2005.16.1194View ArticleGoogle Scholar
- Hojman P, Zibert JR, Gissel H, Eriksen J, Gehl J: Gene expression profiles in skeletal muscle after gene electrotransfer. BMC Mol Biol 2007., 8: 10.1186/1471-2199-8-56Google Scholar
- Schertzer JD, Plant DR, Lynch GS: Optimizing plasmid-based gene transfer for investigating skeletal muscle structure and function. Mol Ther 2006, 13: 795–803. 10.1016/j.ymthe.2005.09.019View ArticleGoogle Scholar
- Andre FM, Gehl J, Sersa G, Preat V, Hojman P, Eriksen J, Golzio M, Cemazar M, Pavselj N, Rols MP, Miklavcic D, Neumann E, Teissie J, Mir LM: Efficiency of High- and Low-Voltage Pulse Combinations for Gene Electrotransfer in Muscle, Liver, Tumor, and Skin. Hum Gene Ther 2008, 19: 1261–1271. 10.1089/hum.2008.060View ArticleGoogle Scholar
- Miyazaki S, Miyazaki JI: In vivo DNA electrotransfer into muscle. Dev Growth Differ 2008, 50: 479–483. 10.1111/j.1440-169X.2008.01025.xView ArticleGoogle Scholar
- Sel D, Cukjati D, Batiuskaite D, Slivnik T, Mir LM, Miklavcic D: Sequential finite element model of tissue electropermeabilization. IEEE Trans Biomed Eng 2005, 52: 816–827. 10.1109/TBME.2005.845212View ArticleGoogle Scholar
- Gehl J, Sorensen TH, Nielsen K, Raskmark P, Nielsen SL, Skovsgaard T, Mir LM: In vivo electroporation of skeletal muscle: threshold, efficacy and relation to electric field distribution. Biochim Biophys Acta Gen Subj 1999, 1428: 233–240. 10.1016/S0304-4165(99)00094-XView ArticleGoogle Scholar
- Corovic S, Pavlin M, Miklavcic D: Analytical and numerical quantification and comparison of the local electric field in the tissue for different electrode configurations. Biomedical Engineering Online 2007., 6: 10.1186/1475-925X-6-37Google Scholar
- Miklavcic D, Semrov D, Mekid H, Mir LM: A validated model of in vivo electric field distribution in tissues for electrochemotherapy and for DNA electrotransfer for gene therapy. Biochim Biophys Acta Gen Subj 2000, 1523: 73–83. 10.1016/S0304-4165(00)00101-XView ArticleGoogle Scholar
- Edd JF, Davalos RV: Mathematical Modeling of irreversible Electroporation for treatment planning. Technol Cancer Res Treat 2007, 6: 275–286.View ArticleGoogle Scholar
- Semrov D, Miklavcic D: Calculation of the electrical parameters in electrochemotherapy of solid tumours in mice. Comput Biol Med 1998, 28: 439–448. 10.1016/S0010-4825(98)00017-1View ArticleGoogle Scholar
- Garcia PA, Rossmeisl JH, Neal RE, Ellis TL, Olson JD, Henao-Guerrero N, Robertson J, Davalos RV: Intracranial nonthermal irreversible electroporation: in vivo analysis. J Memb Biol 2010, 236: 127–136. 10.1007/s00232-010-9284-zView ArticleGoogle Scholar
- Miklavcic D, Beravs K, Semrov D, Cemazar M, Demsar F, Sersa G: The importance of electric field distribution for effective in vivo electroporation of tissues. Biophys J 1998, 74: 2152–2158. 10.1016/S0006-3495(98)77924-XView ArticleGoogle Scholar
- Zupanic A, Miklavcic D: Optimization and numerical modeling in irreversible electroporation treatment planning. In Irreversible electroporation. Berlin: Springer Berlin Heidelberg; 2010:203–222. full_textView ArticleGoogle Scholar
- Corovic S, Zupanic A, Miklavcic D: Numerical modeling and optimization of electric field distribution in subcutaneous tumor treated with electrochemotherapy using needle electrodes. IEEE Trans Plasma Sci 2008, 36: 1665–1672. 10.1109/TPS.2008.2000996View ArticleGoogle Scholar
- Zupanic A, Corovic S, Miklavcic D: Optimization of electrode position and electric pulse amplitude in electrochemotherapy. Radiol Oncol 2008, 42: 93–101. 10.2478/v10019-008-0005-5View ArticleGoogle Scholar
- Miklavcic D, Snoj M, Zupanic A, Kos B, Cemazar M, Kropivnik M, Bracko M, Pecnik T, Gadzijev E, Sersa G: Towards treatment planning and treatment of deep-seated solid tumors by electrochemotherapy. Biomedical Engineering Online 2010, 9: 8. 10.1186/1475-925X-9-10View ArticleGoogle Scholar
- Mir LM, Bureau MF, Gehl J, Rangara R, Rouy D, Caillaud JM, Delaere P, Branellec D, Schwartz B, Scherman D: High-efficiency gene transfer into skeletal muscle mediated by electric pulses. Proc Natl Acad Sci USA 1999, 96: 4262–4267. 10.1073/pnas.96.8.4262View ArticleGoogle Scholar
- Bureau MF, Gehl J, Deleuze V, Mir LM, Scherman D: Importance of association between permeabilization and electrophoretic forces for intramuscular DNA electrotransfer. Biochim Biophys Acta Gen Subj 2000, 1474: 353–359. 10.1016/S0304-4165(00)00028-3View ArticleGoogle Scholar
- Corovic S, Zupanic A, Kranjc S, Al Sakere B, Leroy-Willig A, Mir LM, Miklavcic D: The influence of skeletal muscle anisotropy on electroporation: in vivo study and numerical modeling. Med Biol Eng Comput 2010, 48: 637–648. 10.1007/s11517-010-0614-1View ArticleGoogle Scholar
- Cukjati D, Batiuskaite D, Andre F, Miklavcic D, Mir LM: Real time electroporation control for accurate and safe in vivo non-viral gene therapy. Bioelectrochemistry 2007, 70: 501–507. 10.1016/j.bioelechem.2006.11.001View ArticleGoogle Scholar
- Pavselj N, Bregar Z, Cukjati D, Batiuskaite D, Mir LM, Miklavcic D: The course of tissue permeabilization studied on a mathematical model of a subcutaneous tumor in small animals. IEEE Trans Biomed Eng 2005, 52: 1373–1381. 10.1109/TBME.2005.851524View ArticleGoogle Scholar
- Gabriel C, Peyman A, Grant EH: Electrical conductivity of tissue at frequencies below 1 MHz. Phys Med Biol 2009, 54: 4863–4878. 10.1088/0031-9155/54/16/002View ArticleGoogle Scholar
- Ivorra A, Al-Sakere B, Rubinsky B, Mir LM: Tumor conductivity during electroporation. Phys Med Biol 2009, 54: 5949–5963. 10.1088/0031-9155/54/19/019View ArticleGoogle Scholar
- Ivorra A, Al-Sakere B, Rubinsky B, Mir LM: In vivo electrical conductivity measurements during and after tumor electroporation: conductivity changes reflect the treatment outcome. Phys Med Biol 2009, 54: 5949–5963. 10.1088/0031-9155/54/19/019View ArticleGoogle Scholar
- Rebersek M, Faurie C, Kanduser M, Xorovic S, Teissie J, Rols MP, Miklavcic D: Electroporator with automatic change of electric field direction improves gene electrotransfer in-vitro. Biomedical Engineering Online 2007., 6: 10.1186/1475-925X-6-25Google Scholar
- Faurie U, Phez E, Golzio M, Vossen C, Lesbordes JC, Delteil C, Teissie J, Rols MP: Effect of electric field vectoriality on electrically mediated gene delivery in mammalian cells. Biochim Biophys Acta Biomembr 2004, 1665: 92–100. 10.1016/j.bbamem.2004.06.018View ArticleGoogle Scholar
- Gehl J, Rangara R, Rouy D, Caillaud JM, Delaere P, Branellec D, Schwartz B, Scherman D: High-Efficiency Gene Transfer into Skeletal Muscle Mediated by Electric Pulses. Proc Natl Acad Sci USA 1999, 4262–4267.Google Scholar
- Scheerlinck JPY, Karlis J, Tjelle TE, Presidente PJA, Mathiesen I, Newton SE: In vivo electroporation improves immune responses to DNA vaccination in sheep. Vaccine 2004, 22: 1820–1825. 10.1016/j.vaccine.2003.09.053View ArticleGoogle Scholar
- Wu CJ, Lee SC, Huang HW, Tao MH: In vivo electroporation of skeletal muscles increases the efficacy of Japanese encephalitis virus DNA vaccine. Vaccine 2004, 22: 1457–1464. 10.1016/j.vaccine.2003.10.011View ArticleGoogle Scholar
- Lackovic I, Magjarevic R, Miklavcic D: Three-dimensional finite-element analysis of Joule heating in electrochemotherapy and in vivo gene electrotransfer. IEEE Trans Diel Elec Insul 2009, 16: 1338–1347. 10.1109/TDEI.2009.5293947View ArticleGoogle Scholar
- Shafiee H, Garcia PA, Davalos RV: A Preliminary Study to Delineate Irreversible Electroporation From Thermal Damage Using the Arrhenius Equationa. J Biomech Eng Trans ASME 2009, 131: 5. 10.1115/1.3143027View ArticleGoogle Scholar
- Reed SD, Li S: Electroporation Advances in Large Animals. Current gene therapy 2009, 9: 316–326. 10.2174/156652309788921062View ArticleGoogle Scholar
- Khan AS, Smith LC, Abruzzese RV, Cummings KK, Pope MA, Brown PA, Draghia-Akli R: Optimization of electroporation parameters for the intramuscular delivery of plasmids in pigs. DNA Cell Biol 2003, 22: 807–814. 10.1089/104454903322625019View ArticleGoogle Scholar
- Heller R, Jaroszeski M, Atkin A, Moradpour D, Gilbert R, Wands J, Nicolau C: In vivo gene electroinjection and expression in rat liver. FEBS Lett 1996, 389: 225–228. 10.1016/0014-5793(96)00590-XView ArticleGoogle Scholar
- Terada Y, Tanaka H, Okado T, Inoshita S, Kuwahara M, Akiba T, Sasaki S, Marumo F: Efficient and ligand-dependent regulated erythropoietin production by naked DNA injection and in vivo electroporation. Am J Kidney Dis 2001, 38: S50-S53. 10.1053/ajkd.2001.27398View ArticleGoogle Scholar
- Bettan M, Ivanov MA, Mir LM, Boissiere F, Delaere P, Scherman D: Efficient DNA electrotransfer into tumors. Bioelectrochemistry 2000, 52: 83–90. 10.1016/S0302-4598(00)00087-8View ArticleGoogle Scholar
- Ho S, Hahn W, Lee H, Kim D, Jeong J, Kim S, Yu SS, Jeon E, Kim S, Kim J: Protection against collagen-induced arthritis by electrotransfer of an expression plasmid for the interleukin-4. Biochem Biophys Res Comm 2004, 321: 759–766. 10.1016/j.bbrc.2004.07.028View ArticleGoogle Scholar
- Satkauskas S, Bureau MF, Puc M, Mahfoudi A, Scherman D, Miklavcic D, Mir LM: Mechanisms of in vivo DNA electrotransfer: Respective contributions of cell electropermeabilization and DNA electrophoresis. Mol Ther 2002, 5: 133–140. 10.1006/mthe.2002.0526View ArticleGoogle Scholar
- Tevz G, Pavlin D, Kamensek U, Kranjc S, Mesojednik S, Coer A, Sersa G, Cemazar M: Gene electrotransfer into murine skeletal muscle: A systematic analysis of parameters for long-term gene expression. Technol Cancer Res Treat 2008, 7: 91–101.View ArticleGoogle Scholar
- Tevz G, Kranjc S, Cemazar M, Kamensek U, Coer A, Krzan M, Vidic S, Pavlin D, Sersa G: Controlled systemic release of interleukin-12 after gene electrotransfer to muscle for cancer gene therapy alone or in combination with ionizing radiation in murine sarcomas. J Gene Med 2009, 11: 1125–1137. 10.1002/jgm.1403View ArticleGoogle Scholar
- Hojman P, Gissel H, Andre FM, Cournil-Henrionnet C, Eriksen J, Gehl J, Mir LM: Physiological Effects of High- and Low-Voltage Pulse Combinations for Gene Electrotransfer in Muscle. Hum Gene Ther 2008, 19: 1249–1260. 10.1089/hum.2008.059View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.